Mainz Biomed N.V.

MYNZ

NL0015000LC2

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8181 ^USD	-4.52%		-9.60%	-29.47%

Apr. 25	Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic	CI
Apr. 09	Mainz Biomed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Mainz Biomed N.V.(NasdaqCM:MYNZ) dropped from S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Mainz Biomed N.V.

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic	Apr. 25	CI
Mainz Biomed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 09	CI
Mainz Biomed N.V. Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic	Mar. 05	CI
Mainz Biomed Announces Distribution Partnership with Praxisdienst for Coloalert®	Feb. 22	CI
Mainz Biomed N.V. Establishes Strategic Partnership with Tomalab to Expand Availability of Coloalert in Italy	Feb. 21	CI
Certain Ordinary Shares of Mainz Biomed N.V. are subject to a Lock-Up Agreement Ending on 14-FEB-2024.	Feb. 13	CI
Mainz Biomed Launches New Laboratory in Germany	Feb. 06	MT
Mainz Biomed N.V. and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees	Dec. 19	CI
Mainz Biomed N.V. Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers	Dec. 05	CI
Cantor Fitzgerald Downgrades Mainz Biomed to Neutral From Overweight	Nov. 21	MT
HC Wainwright Adjusts Mainz Biomed's Price Target to $5 From $9, Keeps Buy Rating	Nov. 20	MT
Mainz Biomed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Sector Update: Health Care Stocks Gain in Late Afternoon Trading	Nov. 13	MT
Top Midday Decliners	Nov. 13	MT
Mainz Biomed Targets $5 Million in Direct Offering with Institutional Investors	Nov. 13	MT
Mainz Biomed Nv Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence to Develop Next-Generation Colorectal Screening Test	Nov. 09	CI
Mainz Biomed N.V. Presents Results of Colofuture Study	23-10-18	CI
Mainz Biomed Launches Colorectal Cancer Detection Test in Romania	23-10-04	MT
Mainz Biomed, Bioclinica Introduce Colorectal Cancer Screening Test in Romania	23-10-04	MT
Mainz Biomed N.V. Announces Live Launch of Coloalert® with Bioclinica in Romania	23-10-04	CI
Mainz Biomed N.V. announced that it has received $5.06 million in funding from Yorkville Advisors Global LP	23-09-25	CI
Mainz Biomed N.V.(NasdaqCM:MYNZ) dropped from S&P Global BMI Index	23-09-18	CI
Sector Update: Health Care Stocks Mixed Premarket Wednesday	23-09-13	MT
Mainz Biomed's Colorectal Cancer Screening Trial Yields Positive Topline Results	23-09-13	MT
Mainz Biomed Says Clinical Study Assessing Novel mRNA Biomarkers for Colorectal Cancer Test Showed 'Positive' Results	23-09-13	MT

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Sector

Healthcare Facilities & Services

Calendar

2024-09-03 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mainz Biomed N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8181 USD

Average target price

2 USD

Spread / Average Target

+144.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
MAINZ BIOMED N.V.	-29.47%	17.91M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B
ADICON HOLDINGS LIMITED	-15.34%	1.03B

Medical & Diagnostic Laboratories

Mainz Biomed N.V.

Equities

MYNZ

NL0015000LC2

Healthcare Facilities & Services

Mainz Biomed N.V.(NasdaqCM:MYNZ) dropped from S&P Global BMI Index

Latest news about Mainz Biomed N.V.

Chart Mainz Biomed N.V.

Company Profile

Income Statement Evolution

Ratings for Mainz Biomed N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories